LON:PRM Proteome Sciences (PRM) Share Price, News & Analysis GBX 3.45 +0.05 (+1.47%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range 2.85▼ 3.4550-Day Range 2.82▼ 4.7052-Week Range 2.65▼ 8.71Volume80,762 shsAverage Volume178,373 shsMarket Capitalization£10.18 millionP/E RatioN/ADividend Yield6.17%Price TargetN/A Stock AnalysisStock AnalysisChartCompetitorsHeadlinesStock AnalysisChartCompetitorsHeadlines Get Proteome Sciences alerts: Email Address Ad Weiss RatingsNvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.Find out details on these three critical Nvidia partners immediately. About Proteome Sciences Stock (LON:PRM)Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, European Union, and internationally. The company offers TMT LC-MS2, a standard method for analyzing cells and tissues when no phosphopeptide enrichment is required; TMT LC-MS3, a standard method for biomarker discovery in plasma and other samples where quantitative accuracy is a factor; SysQuant, provides an analysis of protein activity across regulatory and signaling pathways; and TMTcalibrator, analyzes where diseased or treated tissue can be analyzed in parallel with peripheral fluids. It also provides top 14 and top 65 super depletion of proteins from serum and plasma; selective reaction monitoring (SRM) and parallel reaction monitoring (PRM) based biomarker assay development; SRM assay, a targeted mass spectrometry assay format for the routine measurement of biomarkers; and TMT SRM, a targeted assay format that enables the rapid validation of biomarker candidates. The company serves its products to pharmaceutical and biotechnology companies, and academic research institutes. The company was incorporated in 1993 and is based in Cobham, the United Kingdom.Read More PRM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PRM Stock News HeadlinesJuly 17, 2024 | americanbankingnews.comProteome Sciences (LON:PRM) Shares Down 9.8% May 2, 2024 | msn.comProtein profiling reveals impact of aging and resistance training on skeletal muscle proteomeJuly 26, 2024 | American Hartford Gold Group (Ad)Prepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.April 27, 2024 | finance.yahoo.comProteome Sciences Full Year 2023 Earnings: UK£0.008 loss per share (vs UK£0.004 profit in FY 2022)April 11, 2024 | msn.comConsumer microbiome startup Seed Health is rolling its profits into an AI science moonshotMarch 22, 2024 | msn.comResearchers analyze how the proteome of specific brain cells changes as we ageMarch 20, 2024 | uk.finance.yahoo.comProteome Sciences PLC (PRM.AQ)January 22, 2024 | finance.yahoo.comIf EPS Growth Is Important To You, Proteome Sciences (LON:PRM) Presents An OpportunityJuly 26, 2024 | American Hartford Gold Group (Ad)Prepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.January 4, 2024 | proactiveinvestors.com.auProteome Sciences opens lab in San DiegoJanuary 2, 2024 | proactiveinvestors.comProteome Sciences opens lab in San Diego’s biotech hubOctober 2, 2023 | lse.co.ukProteome Sciences sees shares surge on SysQuant service launchAugust 25, 2023 | uk.investing.comFTSE 100 Live: Stocks extend gains ahead of Jackson HoleAugust 25, 2023 | marketwatch.comProteome Sciences Shares Fall After Swing to Loss on Higher CostsAugust 15, 2023 | finance.yahoo.comWe Ran A Stock Scan For Earnings Growth And Proteome Sciences (LON:PRM) Passed With EaseMay 17, 2023 | marketwatch.comProteome Sciences Says It Is Well-Positioned for 2023 GrowthMay 12, 2023 | lse.co.ukProteome Sciences expanding to US with San Diego facilityApril 29, 2023 | fool.co.ukProteome SciencesSee More Headlines Receive PRM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Proteome Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/10/2020Today7/26/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Diagnostics & Research Sub-IndustryN/A Current SymbolLON:PRM CUSIPN/A CIKN/A Webwww.proteomics.com Phone+44-20-70432116FaxN/AEmployees35Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (0.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-2,440,000.00 Net Margins-48.59% Pretax MarginN/A Return on EquityN/A Return on Assets-8.48% Debt Debt-to-Equity RatioN/A Current Ratio0.33 Quick Ratio0.37 Sales & Book Value Annual Sales£5.03 million Price / Sales2.02 Cash FlowGBX 0.93 per share Price / Cash Flow3.73 Book ValueGBX (1) per share Price / Book-3.45Miscellaneous Outstanding Shares295,180,000Free FloatN/AMarket Cap£10.18 million OptionableNot Optionable Beta-0.03 Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.Get This Free Report Key ExecutivesDr. Mariola Sohngen (Age 63)CEO & Executive Director Comp: $261kMr. Abdelghani Omari (Age 48)CFO & Director Comp: $212kDr. Ian H. Pike (Age 60)Chief Scientific Officer & Executive Director Comp: $245kMr. Richard Paul Dennis (Age 66)Chief Commercial Officer & Executive Director Comp: $207kVictoria Joanna BirseCompany SecretaryKey CompetitorsANGLELON:AGLVerici DxLON:VRCIYourgene HealthLON:YGENAbingdon HealthLON:ABDXGENinCodeLON:GENIView All Competitors PRM Stock Analysis - Frequently Asked Questions How have PRM shares performed this year? Proteome Sciences' stock was trading at GBX 4.53 at the start of the year. Since then, PRM stock has decreased by 23.8% and is now trading at GBX 3.45. View the best growth stocks for 2024 here. How were Proteome Sciences' earnings last quarter? Proteome Sciences plc (LON:PRM) released its quarterly earnings data on Monday, August, 10th. The company reported ($0.17) EPS for the quarter. How do I buy shares of Proteome Sciences? Shares of PRM stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. What other stocks do shareholders of Proteome Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Proteome Sciences investors own include ValiRx (VAL), boohoo group (BOO), Mondi (MNDI), Petrofac (PFC), Lloyds Banking Group (LLOY), Falanx Group (FLX) and Quanterix (QTRX). This page (LON:PRM) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Proteome Sciences plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Proteome Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
